Dudediligence.

Maze Therapeutics, Inc

MAZENASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$2.5MSep ’24$0.00Dec ’24$0.00Jun ’25$20.0MMar ’26
Net income, by quarter
−$24.8MSep ’24−$29.6MDec ’24−$32.8MMar ’25−$33.7MJun ’25−$30.1MSep ’25−$34.6MDec ’25−$24.2MMar ’26−$44.7MJun ’26
Fiscal years, by the month each ended
LineDec 2023Dec 2024Dec 2025
Revenuenone on file$167.5Mnone on file
Operating incomenone on file$57.6M−$142.9M
Net incomenone on file$52.2M−$131.1M
Operating cash flownone on file$76.0M−$111.9M
Free cash flownone on file$74.8M−$112.7M
Cash$30.2M$196.8M$189.2M
Shares outstandingnone on file2.4M49.3M
MAZE fundamentals · DudeDiligence